estrogen receptor
Pfizer, Carrick Therapeutics, Arvinas Partner to Study Combination Therapy in Breast Cancer
The firms will explore the activity of Carrick's samuraciclib with Arvinas' vepdegestrant in ER-positive, HER2-negative breast cancer.
The firm is seeing the fruit of a two-year investment in transitioning from a research lab to a clinical focus.
Effector Therapeutics Pairs With Stanford Medicine to Study Zotatifin in High-Risk Breast Cancer
The trial will include patients with ER-positive, HER2-negative breast cancer, including a cohort with biomarker-defined high-risk disease.
Sermonix Pharma Using Guardant Health CDx to Screen Breast Cancer Patients for Lasofoxifene Trial
The ELAINE-3 study, a Phase III trial, will use the Guardant360 CDx liquid biopsy test to screen patients for ESR1 mutations.
Lantern Pharma, TTC Oncology Ink Biomarker Discovery, Licensing Deal for Breast Cancer Drug
The collaboration is focused on identifying biomarkers of benefit and potential treatment indications for TTC Oncology's estrogen receptor agonist TTC-352.